Drug Profile
Teriparatide biosimilar - Intas Pharmaceuticals
Alternative Names: INTG8; Parathyroid hormone - Intas Pharmaceuticals; PTH - Intas Pharmaceuticals; TerifracLatest Information Update: 25 Jan 2023
Price :
$50
*
At a glance
- Originator Intas Pharmaceuticals
- Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Parathyroid hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Osteoporosis
- Phase III Fracture
Most Recent Events
- 25 Jan 2023 Intas Pharmaceuticals completes a phase I bioequivalence trial in Healthy volunteers (SC) as of January 2023 (CTRI-2020-10-028627)
- 28 Sep 2021 Teriparatide biosimilar is still in phase III trials for Fracture in India (SC, Injection)
- 22 Oct 2020 Intas Pharmaceuticals plans a phase I bioequivalence trial in healthy volunteers in India in October 2020 (SC) (CTRI2020-10-028627),